Keywords: rotateq, prevents, severe, rotavirus, gastroenteritis, oral, vaccine
RotaTeq prevents 98% of severe rotavirus gastroenteritis
Article | 09 January 2006
RotaTeq (oral, rotavirus vaccine, live, pentavalent (G1, G2, G3, G4 and P1[8]), Sanofi Pasteur MSD's rotavirus vaccine in development, prevented 98% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
